Is AbbVie bigger than Pfizer?

Both companies are significant players in their respective markets. See the financial comparison table above for current market capitalization data.

Which has better profit margins — AbbVie or Pfizer?

Pfizer has higher net profit margins (11.8%) compared to AbbVie (9.8%). Gross and operating margins are compared in the table above.

What sectors do AbbVie and Pfizer operate in?

AbbVie operates in the Healthcare sector (Drug Manufacturers - General). Pfizer operates in the Healthcare sector (Drug Manufacturers - General).

How does AbbVie's revenue compare to Pfizer's?

AbbVie generates $64.39B in annual revenue (TTM) while Pfizer generates $63.32B. AbbVie is the larger company by revenue as of 2026.

AbbVievsPfizer

AbbVie vs Pfizer: Business Model & Financial Comparison 2026

AbbVie · Healthcare / Drug Manufacturers - General·Pfizer · Healthcare / Drug Manufacturers - General

Financial Comparison

Metric	ABBVAbbVie	PFEPfizer
Market Cap	$443.36B	N/A
Revenue (TTM)	$64.39B	$63.32B
Revenue Growth	10.2%	5.4%
Gross Margin	72.8%	74.8%
Operating Margin	39.6%	31.6%
Net Margin	9.8%	11.8%
Return on Equity	N/A	8.3%
P/E (Trailing)	70.9x	19.1x
P/E (Forward)	15.4x	8.8x
Free Cash Flow	N/A	$12.38B
Cash	$9.39B	$13.08B
Total Debt	$72.91B	$64.73B

Data sourced from Yahoo Finance. Green highlights indicate better performance for that metric. Use the interactive tool for real-time data.

Business Model Comparison

AbbVie

AbbVie Inc. stands as a leading company in Healthcare. Generating $61.16 billion in annual revenue (growing 10.0% year-over-year) and carrying a market capitalization of $410.83 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, AbbVie Inc. continues to execute on a multi-year strategic vision that balances growth investment wit…

Full AbbVie analysis →

Pfizer

Pfizer Inc. stands as a leading company in Healthcare. Generating $62.58 billion in annual revenue (growing -1.2% year-over-year) and carrying a market capitalization of $151.30 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, Pfizer Inc. continues to execute on a multi-year strategic vision that balances growth investment wit…

Full Pfizer analysis →

SWOT Analysis Comparison

Strengths

AbbVie

With a market capitalization of $410.83B, AbbVie Inc. is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital access that sma
AbbVie Inc.'s gross margin of 71.6% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 34.1% demonstrates disciplin
A return on equity of 6225.0% demonstrates that AbbVie Inc. generates strong returns from shareholder capital, a hallmark of companies with durable competitive advantages.

Pfizer

With a market capitalization of $151.30B, Pfizer Inc. is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital access that sma
Pfizer Inc.'s gross margin of 75.8% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 23.9% demonstrates disciplin
Pfizer Inc. generated $13.43B in free cash flow, providing financial flexibility to invest in growth initiatives, return capital to shareholders, or strengthen the balance sheet.

Weaknesses

AbbVie

In the Drug Manufacturers - General sector, larger competitors with greater economies of scale can exert pricing pressure and outspend AbbVie Inc. on marketing, R&D, and distribution — limiting the co
Revenue concentration in core markets or customer segments creates vulnerability to localized downturns, regulatory changes, or shifts in customer preferences. Diversification remains an ongoing strat

Pfizer

Pfizer Inc.'s debt-to-equity ratio of 78.0 indicates meaningful financial leverage. Total debt stands at $67.65B against $13.60B in cash and equivalents.
Year-over-year revenue declined 1.2%, raising questions about demand for Pfizer Inc.'s core offerings and requiring management to articulate a credible recovery path.

Opportunities

AbbVie

AbbVie Inc. operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this env
Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for AbbVie
With $5.26B in cash and strong free cash flow generation, AbbVie Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Pfizer

Pfizer Inc. operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this env
Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Pfizer
With $13.60B in cash and strong free cash flow generation, Pfizer Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

AbbVie

Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. AbbVie Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scen
Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on AbbVie Inc.'s busin
Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri

Pfizer

Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Pfizer Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scen
Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Pfizer Inc.'s busin
Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri

Compare any 2–4 companies with live data

The interactive comparison tool lets you select any companies, see real-time metrics, and export a side-by-side report.

Open Comparison Tool

AbbVie vs Pfizer: FAQ

Is AbbVie bigger than Pfizer?: Both companies are significant players in their respective markets. See the financial comparison table above for current market capitalization data.
Which has better profit margins — AbbVie or Pfizer?: Pfizer has higher net profit margins (11.8%) compared to AbbVie (9.8%). Gross and operating margins are compared in the table above.
What sectors do AbbVie and Pfizer operate in?: AbbVie operates in the Healthcare sector (Drug Manufacturers - General). Pfizer operates in the Healthcare sector (Drug Manufacturers - General).
How does AbbVie's revenue compare to Pfizer's?: AbbVie generates $64.39B in annual revenue (TTM) while Pfizer generates $63.32B. AbbVie is the larger company by revenue as of 2026.